4.7 Article

Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, General & Internal

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M. M. Eggermont et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Review Immunology

The diverse functions of the PD1 inhibitory pathway

Arlene H. Sharpe et al.

NATURE REVIEWS IMMUNOLOGY (2018)

Editorial Material Oncology

iRECIST: A clarification of tumour response assessment in the immunotherapy era

Charles Ferte et al.

EUROPEAN JOURNAL OF CANCER (2017)

Meeting Abstract Oncology

Pseudoprogression in cancer immunotherapy: Rates, time course and patient outcomes

Vikram Kurra et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Article Radiology, Nuclear Medicine & Medical Imaging

A Response Assessment Platform for Development and Validation of Imaging Biomarkers in Oncology

Hao Yang et al.

TOMOGRAPHY (2016)

Editorial Material Oncology

Pseudoprogression and Immune-Related Response in Solid Tumors

Victoria L. Chiou et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Meeting Abstract Oncology

Adaptation and modification of the immune related response criteria (IRRC): IrRECIST

Oliver Bohnsack et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)